leisure time -WSS

leisure time

author：leisure time 2025-09-07 11:14:34 - browse：1

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Gene editing the human germline: What are the risks?

WSS

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Argenx readies a blockbuster opportunity with drug for autoimmune disease

'Weather

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

leisure time

leisure time

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Asbestos, a deadly carcinogen, banned by EPA

Hepatitis C has a cure — but many Americans still lack access to it

Doctors in states that ban abortion can still help patients

Moonlake's readout produced a cash windfall. Risks remain

Plastic surgeons increase patient psychiatric screenings

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Snowpack in the West is melting rapidly. Where will all that extra water go?

Medical leaders decry Supreme Court decision on affirmative action

Europe is fastest

knowledge

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Methadone treatment changes are coming. Do they go far enough?

Doctors in states that ban abortion can still help patients

Intermittent fasting comes with a heart risk? Not so fast

Physicians and social media: If you see something, say something?

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

hotspot

hotspot

hotspot

leisure time